Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Abstract Deficiency in host defences allows infections to occur with greater frequency. Their nature and presentation may be unusual and hence diagnosis may be difficult. The type, severity and duration of immunocompromise determine the infections to which the host is vulnerable. Unlike in primary immunocompromised patients, the susceptibility of secondary immunocompromised patients often changes during the course of their illness as their immune function may vary with the use of immunosuppressive drugs or highly active anti‐retroviral agents prescribed for those with human immunodeficiency virus. There is an ever‐increasing number of new agents that modify the host immune response. These include biologic therapies that target specific cytokines and are used in various inflammatory disorders. The growing numbers of immunocompromised patients make this a key area for those involved in managing infections. A number of strategies are employed to combat the infectious threat ranging from prophylaxis to pre‐emptive, empirical and definitive treatment. Key Concepts Immunocompromised patients are susceptible to a range of opportunistic infections due to deficiencies in their immune defences. Opportunistic infections occur in immunocompromised but not immunocompetent hosts. Specific immune defects may predispose to a restricted range of opportunistic infections. Immune defects may involve innate (antigen non‐specific) or adaptive (antigen specific) responses. Clinical features may be modified or less apparent in the presence of immunodeficiency. The diagnosis of an infection requires consideration of infectious exposures, details of immunodeficiency and all clinical features and investigation results. Clinical illness may be prevented by screening and treating latent infection, prophylaxis or pre‐emptive treatment in the subclinical phase if markers of infection progression are available.

More information Original publication

DOI

10.1002/9780470015902.a0002224.pub3

Type

Chapter

Publisher

Wiley

Publication Date

2015-02-16T00:00:00+00:00

Pages

1 - 12

Total pages

11